82 related articles for article (PubMed ID: 21031422)
1. Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age.
Onozato W; Yamashita K; Yamashita K; Kuba T; Katoh H; Nakamura T; Sato T; Ihara A; Okayasu I; Watanabe M
J Surg Oncol; 2011 Jan; 103(1):25-33. PubMed ID: 21031422
[TBL] [Abstract][Full Text] [Related]
2. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
3. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer.
Pajkos G; Kiss I; Sándor J; Ember I; Kisházi P
Anticancer Res; 2000; 20(3A):1695-701. PubMed ID: 10928094
[TBL] [Abstract][Full Text] [Related]
5. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
7. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process.
Losi L; Luppi G; Benhattar J
Oncol Rep; 2004 Dec; 12(6):1221-5. PubMed ID: 15547741
[TBL] [Abstract][Full Text] [Related]
8. Correlation of K-ras codon 12 mutations in human feces and ages of patients with colorectal cancer (CRC).
Chien CC; Chen SH; Liu CC; Lee CL; Yang RN; Yang SH; Huang CJ
Transl Res; 2007 Feb; 149(2):96-102. PubMed ID: 17240321
[TBL] [Abstract][Full Text] [Related]
9. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
10. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
[TBL] [Abstract][Full Text] [Related]
11. [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients].
Amosenko FA; Korchagina EL; Matveeva TI; Vaganov IuE; Vlasov SB; Poltavets NV; Veselov VV; Gar'kavtseva RF; Poliakov AV
Genetika; 2010 May; 46(5):700-8. PubMed ID: 20583607
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.
Minamoto T; Mai M; Ronai Z
Cancer Detect Prev; 2000; 24(1):1-12. PubMed ID: 10757118
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer prognosis: is it all mutation, mutation, mutation?
Hassan AB; Paraskeva C
Gut; 2005 Sep; 54(9):1209-11. PubMed ID: 16099785
[TBL] [Abstract][Full Text] [Related]
14. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
Li M; Li JY; Zhao AL; Gu J
Oncology; 2007; 73(1-2):52-7. PubMed ID: 18334831
[TBL] [Abstract][Full Text] [Related]
16. Combined analysis of microsatellite instability and K-ras mutation increases detection incidence of normal samples from colorectal cancer patients.
Minamoto T; Esumi H; Ochiai A; Belitsky G; Mai M; Sugimura T; Ronai Z
Clin Cancer Res; 1997 Aug; 3(8):1413-7. PubMed ID: 9815826
[TBL] [Abstract][Full Text] [Related]
17. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
18. Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications.
Schimanski CC; Linnemann U; Galle PR; Arbogast R; Berger MR
Int J Oncol; 2003 Sep; 23(3):791-6. PubMed ID: 12888919
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.
Fujii S; Fujimori T; Chiba T
J Exp Clin Cancer Res; 2003 Mar; 22(1):107-15. PubMed ID: 12725330
[TBL] [Abstract][Full Text] [Related]
20. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
